Table 5. Comparison results of selected biomarkers associated with acute or chronic kidney injuries in the cohort population overall and by MAT titers at follow-up in 2011.
| Biomarkers | Total (n = 88) | MAT = 0 (n = 32) | MAT = 100–200 (n = 39) | MAT≥400 (n = 17) |
|---|---|---|---|---|
| NGAL Serum (ng/ml) | 78.5 ± 36.4 | 79.1 ± 39.9 | 74.8 ± 36.1 | 82.2 ± 34.0 |
| NGAL Urine (ng/ml) | 34.9 ± 63.2 | 45.4 ± 87.0 | 27.0 ± 47.2 | 31.0 ± 43.4 |
| KIM1/Cr (ng/mg) 1 , 3 , 4 | 0.609 ± 0.346 | 0.569 ± 0.34 | 0.544 ± 0.327 | 0.826 ± 0.322 |
| MCP1 (pg/ml) | 229.5 ± 152.7 | 261.9 ± 177.3 | 194.8 ± 127.5 | 250.1 ± 148.6 |
1 P<0.05 for oneway ANOVA between MAT = 1, MAT≥ 100, and MAT≥400.
2 P<0.05 for MAT = 0 vs MAT≥ 100.
3 P<0.05 for MAT = 0 vs MAT≥ 400.
4 P<0.05 for MAT≥ 100 vs MAT≥ 400.
5neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule–1 creatinine ratio (KIM–1/Cr), and monocyte chemoattractant protein–1 (MCP–1).